Dr. Henry Ji to Participate In Financing Expert Panel at East/West CEO Conference
January 04, 2019 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Jan. 04, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento") announced today that Dr. Henry Ji, Chairman and CEO, will participate in the East/West CEO...
Sorrento Therapeutics Closes Five-Year Term Loan Financing for Up to $150 Million
November 08, 2018 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), a clinical-stage immunotherapy biotech company, announces the closing of a debt financing for up to $150...
Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases
November 06, 2018 08:01 ET
|
Sorrento Therapeutics, Inc.
Two out of four patients showed complete resolution of liver metastases on PET scanMedian overall survival (OS) 8.3 months and mean OS 9.8 months, compared to the standard of care 3 to 6 monthsMeeting...
Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma
November 01, 2018 07:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an innovative immunotherapy company, announced today that the first patients were dosed in a Phase 1 study to...
Scilex Announces the Availability of ZTlido™
October 01, 2018 08:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Oct. 01, 2018 (GLOBE NEWSWIRE) -- Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), announced that ZTlido™ (lidocaine topical...
Sorrento Therapeutics to Present at the Leerink Partners Roundtable Series 10/3/2018
September 27, 2018 18:09 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc (Nasdaq: SRNE, “Sorrento”), a clinical stage, antibody-centric, biopharmaceutical company developing new therapies today...
Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018
September 19, 2018 08:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Scilex Pharmaceuticals Inc. (Scilex), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (Sorrento), today announced that the Wholesale...
Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication
September 10, 2018 04:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 10, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE) (“Sorrento”) announced today that its majority-owned subsidiary, Scilex Pharmaceuticals Inc. (“Scilex”),...
Sorrento Therapeutics to Present at FB Riley and HC Wainwright Sept 2018 Healthcare Conferences in NYC (NY)
September 02, 2018 13:19 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Sept. 02, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will be participating in upcoming...
1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations
August 13, 2018 04:00 ET
|
Sorrento Therapeutics, Inc.
SAN DIEGO, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE, "Sorrento"), announced that the first enrolled patient in the phase 1b study of its non-opioid, afferent nerve...